Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial

Schizophrenia Research
Del D MillerJ Lieberman

Abstract

To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. Baseline data on 1460 patients with schizophrenia were collected as part of the Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Multiple regression analyses were used to examine the relationship between TD and clinical variables. 212 subjects met the Schooler-Kane criteria for probable TD and 1098 had no history or current evidence of TD. Subjects with TD were older, had a longer duration of receiving antipsychotic medication, and were more likely to have been receiving a conventional antipsychotic and an anticholinergic agent. After controlling for important baseline covariates, diabetes mellitus (DM) and hypertension did not predict TD, whereas substance abuse significantly predicted TD. Differences in cognitive functioning were not significantly different after controlling for baseline covariates. The TD subjects also had higher ratings of psychopathology, EPSE, and akathisia. Our results confirm the established relationships between the presence of TD a...Continue Reading

References

Feb 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·E J DavisL N Sharma
Sep 1, 1992·The American Journal of Psychiatry·R YassaM Thibeau
Jan 1, 1992·Schizophrenia Bulletin·R Yassa, Dilip V Jeste
Feb 1, 1992·Psychological Medicine·J V Lucey, T G Dinan
Mar 1, 1991·Archives of General Psychiatry·L GanziniDaniel E Casey
Nov 6, 1991·JAMA : the Journal of the American Medical Association·Bruce L SaltzK Kahaner
Jan 1, 1990·The American Journal of Drug and Alcohol Abuse·A A OliveraN K Manley
Jan 15, 1990·Biological Psychiatry·T C ManschreckP Collins
Jan 1, 1990·Schizophrenia Bulletin·R E DrakeM S Beaudett
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Nov 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·John Waddington, H A Youssef
Jan 1, 1986·Psychopharmacology Bulletin·J LiebermanJ Ramos-Lorenzi
Jan 1, 1987·Schizophrenia Bulletin·S R KayL Opler
Feb 1, 1985·Archives of General Psychiatry·S MukherjeeH A Sackeim
Oct 1, 1972·The American Journal of Psychiatry·G E Crane
Mar 1, 1981·The American Journal of Psychiatry·Dilip V Jeste, R J Wyatt
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, John Kane
Feb 1, 1983·The American Journal of Psychiatry·G Gardos, J O Cole
Jan 1, 1983·Psychopharmacology·J G CsernanskyL E Hollister
Jun 1, 1984·Archives of General Psychiatry·William M GlazerHal Morgenstern
Jun 1, 1984·The Journal of Nervous and Mental Disease·L OplerJ P Lindenmayer
Jul 1, 1984·Comprehensive Psychiatry·J P LindenmayerL Opler
Sep 1, 1995·Archives of General Psychiatry·Dilip V JesteL A McAdams
Jun 1, 1993·The American Journal of Psychiatry·M G WoernerJ M Alvir
Apr 1, 1996·Archives of General Psychiatry·Miranda H ChakosJ Lieberman
Aug 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·M LaruelleR B Innis
Jan 1, 1996·Schizophrenia Bulletin·D Umbricht, John Kane
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJohn Kane
Oct 3, 2002·The American Journal of Psychiatry·Rita Z Goldstein, Nora D Volkow
Dec 28, 2002·Diabetes Care·Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Sep 5, 2003·The New England Journal of Medicine·Jordi Camí, Magí Farré
Jul 1, 1962·The Journal of Nervous and Mental Disease·R DRUCKMANB THULIN
Dec 6, 2003·Hypertension·Aram V ChobanianNational High Blood Pressure Education Program Coordinating Committee

Citations

Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Del D MillerClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jul 31, 2008·Journal of Psychiatric Practice·Caroline Bonham, Christopher Abbott
Sep 25, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Iris GrossmanDavid B Goldstein
Feb 5, 2009·The Journal of Clinical Psychiatry·Theodore D SatterthwaiteStanley N Caroff
Sep 8, 2010·The Journal of Clinical Psychiatry·Stanley N CaroffCATIE Investigators
Apr 24, 2013·Journal of Clinical Psychopharmacology·Daniel M BlumbergerBarnett S Meyers
Dec 24, 2013·Journal of Psychiatry & Neuroscience : JPN·Gary Remington, Margaret Hahn
Sep 11, 2008·Pharmacogenomics·Bk ThelmaArun Kumar Tiwari
Jun 17, 2006·International Review of Psychiatry·Krishna VaddadiJohn Waddington
May 7, 2009·Expert Opinion on Drug Metabolism & Toxicology·Iris Grossman
Dec 22, 2010·Neurologic Clinics·Stanley N CaroffE Cabrina Campbell
Sep 14, 2010·Clinics in Laboratory Medicine·Adriana FosterPeter F Buckley
Nov 3, 2010·L'Encéphale·C DemilyGuy Chouinard
Jun 30, 2010·Journal of Neurodevelopmental Disorders·Agustini UtariRandi J Hagerman
Aug 28, 2007·The Psychiatric Clinics of North America·Adriana FosterPeter F Buckley
Mar 6, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pierre Thomas
Aug 21, 2008·Australasian Journal on Ageing·John TillerIsaac Schweitzer
Jun 23, 2011·Human Psychopharmacology·Maria VaresErik G Jönsson
Jul 30, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Simon ZhornitskyStéphane Potvin
Aug 14, 2012·Human Psychopharmacology·Ina RissanenJouko Miettunen
May 29, 2009·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Huei-Ting TsaiP F Sullivan
Apr 10, 2009·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Huei-Ting TsaiCharles Poole
Oct 4, 2012·Schizophrenia Research·Yoichiro TakayanagiWilliam W Eaton
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Michael Soyka, Susanne Roesner
Dec 5, 2014·Schizophrenia Research·Gagan FervahaGary Remington
Dec 3, 2011·Journal of the Neurological Sciences·Priya JagotaAnthony E Lang
Jun 14, 2014·European Archives of Psychiatry and Clinical Neuroscience·Stéphane PotvinEmmanuel Stip
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Jul 30, 2016·Pharmacogenomics·Rachel K LanningDaniel J Müller
Dec 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaWFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Oct 10, 2007·Harvard Review of Psychiatry·T C Manschreck, Roger A Boshes
Feb 1, 2017·Journal of Clinical Psychopharmacology·Thierry Q MentzelGenetic Risk and Outcome of Psychosis (GROUP) Investigators
Mar 13, 2018·Current Opinion in Psychiatry·Clement C ZaiJames L Kennedy
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Jun 15, 2018·International Journal of Methods in Psychiatric Research·Fei YeXiaobin Zhang
Nov 20, 2013·The Cochrane Database of Systematic Reviews·Laila AsmalStefan Leucht
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·T S Stroup, Neil Gray
Sep 8, 2017·CNS Spectrums·Martin StrassnigPhilip D Harvey
Jul 16, 2008·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Mar 12, 2008·Current Opinion in Psychiatry·Christoph U Correll, Eva M Schenk
Oct 20, 2005·The Cochrane Database of Systematic Reviews·W L ChuaA Mortimer
Jun 22, 2006·Harvard Review of Psychiatry·Arshia A Shirzadi, S Nassir Ghaemi
Feb 15, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaWFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Dec 16, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Chun-Rong LiIk-Keun Hwang
Feb 4, 2010·The Journal of Medical Humanities·Lisa Diedrich
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Adib Essali, Ghassan Ali
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Jul 1, 2014·Expert Review of Neurotherapeutics·Maya GuptaChristopher Bowie
Dec 14, 2019·Journal of Clinical Psychopharmacology·Stanley N CaroffE Cabrina Campbell
Feb 6, 2019·Current Opinion in Psychiatry·Christian G Widschwendter, Alex Hofer
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Sep 28, 2017·International Journal of Psychiatry in Clinical Practice·Nimisha DesaiEla Vatsala
Sep 25, 2020·Pharmacogenomics·Justin Y LuClement C Zai
Oct 28, 2015·Journal of Clinical Psychopharmacology·Margarita Garcia-AmadorCelso Arango
Feb 23, 2019·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Lucia RicciardiMark Edwards
Oct 31, 2007·CNS Spectrums·Naveed IqbalPrakash Masand
Mar 19, 2008·Molecular Psychiatry·P F SullivanS L Close
Jan 24, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Palmiero MonteleoneItalian Network for Research on Psychoses
Apr 14, 2020·Neurologic Clinics·Hassaan H Bashir, Joseph Jankovic
Feb 20, 2021·The South African Journal of Psychiatry : SAJP : the Journal of the Society of Psychiatrists of South Africa·Francois-Pierre JoubertLaila Asmal

Related Concepts

Overinclusion
Diabetes Mellitus, Non-Insulin-Dependent
Dyskinesia, Medication-Induced
Hypertensive Disease
Memory for Designs Test
Akathisia
Risk-Taking
Schizophrenia
Severity of Illness Index
Antipsychotic Effect

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here